Sutro Biopharma (STRO) Common Equity (2016 - 2025)
Sutro Biopharma (STRO) has disclosed Common Equity for 10 consecutive years, with -$132.5 million as the latest value for Q4 2025.
- Quarterly Common Equity fell 396.97% to -$132.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$132.5 million through Dec 2025, down 396.97% year-over-year, with the annual reading at -$132.5 million for FY2025, 396.97% down from the prior year.
- Common Equity hit -$132.5 million in Q4 2025 for Sutro Biopharma, down from -$87.3 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $307.5 million in Q2 2021 to a low of -$132.5 million in Q4 2025.
- Historically, Common Equity has averaged $137.9 million across 5 years, with a median of $153.4 million in 2023.
- Biggest five-year swings in Common Equity: surged 274.41% in 2021 and later plummeted 396.97% in 2025.
- Year by year, Common Equity stood at $252.6 million in 2021, then dropped by 14.06% to $217.0 million in 2022, then crashed by 31.05% to $149.6 million in 2023, then tumbled by 70.2% to $44.6 million in 2024, then crashed by 396.97% to -$132.5 million in 2025.
- Business Quant data shows Common Equity for STRO at -$132.5 million in Q4 2025, -$87.3 million in Q3 2025, and -$32.1 million in Q2 2025.